Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus EVOCLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus EVOCLIN.
BACTROBAN vs EVOCLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic